Median survival extended by 5.7 months! Roche's (RHHBY.US) new lung cancer drug wins in head-to-head trial, major catalyst for oncology business

Title context: Median survival extended by 5.7 months! Roche's (RHHBY.US) new lung cancer drug wins in head-to-head trial, major catalyst for oncology business Text: Roche, the Swiss healthcare and pharmaceutical supergiant, reported that its investigational lung cancer drug divarasib extended median survival by nearly six months compared with competing therapies in a late-stage clinical trial, potentially further strengthening the Swiss drugmaker's oncology portfolio. In patients with advanced non-small cell lung cancer driven by the KRAS G12C gene mutation, the therapy outperformed sotorasib from biopharma giant Amgen (AMGN.US) and adagrasib, a blockbuster drug under Bristol-Myers Squibb Company (BMY.US). These trial participants had previously received other treatments, including chemotherapy. The results were presented on Sunday at the European Society for Medical Oncology Congress in Madrid. The study directly compared divarasib with existing KRAS G12C inhibitors rather than with chemotherapy, providing evidence of its potential advantage over established therapies. Researchers also reported that the drug had a favorable safety profile, consistent with previous findings on divarasib and other drugs in the same class. Fewer patients experienced serious adverse events or discontinued treatment because of side effects. Wall Street analysts surveyed by institutions almost unanimously expect divarasib annual sales to exceed 1 billion Swiss francs ($1.3 billion) by 2032; if approved, it could become an important revenue source for Roche's oncology business. Roche is running additional trials evaluating divarasib in earlier stages of lung cancer treatment. One study combines it with Keytruda, the blockbuster cancer therapy from U.S. healthcare giant Merck & Co., Inc. (MRK.US), exploring the possibility of offering a chemotherapy-free regimen for newly diagnosed patients; another study examines its use after surgery to reduce the risk of cancer recurrence. Extending survival by 5.7 months: Roche strengthens competitiveness of new lung cancer drug with head-to-head trial The core breakthrough Roche announced this time is that, in previously treated patients with KRAS G12C-mutant advanced non-small cell lung cancer, divarasib improved both disease control and overall survival compared with the existing targeted-drug control group. The Phase III Krascendo 1 trial, disclosed on October 25 at the European Society for Medical Oncology (ESMO) Congress, enrolled 338 patients: the divarasib group achieved median overall survival (OS) of 17.7 months, compared with 12.0 months in the control group, an extension of 5.7 months and a 44% relative reduction in the risk of death; median progression-free survival (PFS) was extended from 5.7 months to 9.8 months. This direct comparison was against an existing targeted-drug control group consisting of Amgen's sotorasib and Bristol-Myers Squibb Company's adagrasib, providing relatively strong evidence for the new drug's effort to secure a clinical position. "Head-to-Head" refers to assigning patients to different treatment groups in the same clinical trial to directly compare the efficacy and safety of drugs. In this case, Roche's divarasib was compared with a control group using sotorasib or adagrasib. The underlying mechanism behind divarasib is that the KRAS G12C mutation makes cell growth signals abnormally active, and divarasib precisely binds the mutant protein to inhibit the driver signals on which tumors depend for growth. KRAS is originally a molecular switch that regulates cell proliferation, and G12C means that glycine at position 12 of the protein is replaced by cysteine. Divarasib is a covalent inhibitor that can stabilize the mutant protein in an inactive state bound to guanosine diphosphate (GDP), blocking downstream pro-proliferative signals. It is understood that a preclinical study showed that its potency and selectivity were higher than those of existing drugs, providing a pharmacological basis for more fully inhibiting the target. Clinical benefit was also accompanied by better tolerability: the incidence of serious treatment-related adverse events was 7.8%, compared with 15.2% in the control group; the proportion of patients discontinuing treatment due to treatment-related adverse events was 4.8%, compared with 11.7% in the control group. Better disease control and fewer toxicity-related discontinuations together support sustained treatment. From clinical advantage to sales increment: Roche competes for the next round of growth in its oncology business For Roche's ADR shares in the U.S. market (RHHBY.US) as well as its European-listed shares themselves, the investment value lies in the fact that survival data directly superior to existing drugs are expected to increase clinical adoption of divarasib after approval and enhance its ability to compete for market share. A Bloomberg analyst survey cited in the report estimates that annual sales of the drug will exceed 1 billion Swiss francs by 2032, about $1.3 billion. This potential increment is of practical significance to Roche the company's third-quarter sales were 16.13 billion Swiss francs, up 7% at constant exchange rates, but sales of the mature product Xolair fell short of expectations due to competition from lower-priced competing products. From this perspective, the commercial value of the new drug needs to be translated into differentiated efficacy, prescription penetration and incremental revenue to help the company continue the growth of mature products. Greater growth room comes from moving treatment earlier. Krascendo 2 is testing whether divarasib combined with pembrolizumab (Keytruda) can enter first-line treatment of untreated advanced lung cancer as a chemotherapy-free regimen; Krascendo 3 is studying its value in adjuvant treatment after surgery for resectable lung cancer. The former works through the synergy of targeted inhibition of tumor driver signals and relief of immune suppression, while the latter focuses on controlling residual cancer cells after surgery and reducing the risk of recurrence. The two paths respectively expand treatment-line and disease-stage coverage: if subsequent trials succeed and the drug is approved, divarasib's market space is expected to extend from previously treated patients to a broader applicable population. This is also the main basis for further enhancing its long-term sales potential.